Efficacy of Danshen Chuanxiongqin Injection Combined with Standard Western Therapy in Acute Coronary Syndrome: A Prospective Cohort Study

Abstract

This prospective cohort study evaluates the clinical efficacy of Danshen Chuanxiongqin (DSCXQ) injection, a Traditional Chinese Medicine (TCM) when used in conjunction with standard Western medical therapy in patients with Acute Coronary Syndrome (ACS). Conducted at Jinan Fuyuan Rehabilitation Hospital, China, the study involved 140 ACS patients randomized into two groups: treatment (n=70) receiving DSCXQ and standard therapy, and control (n=70) receiving only standard therapy. The primary outcomes measured were changes in serum levels of D-Dimer, BNP, Troponin, and cardiac ejection fraction (EF). The results revealed significant improvements in all primary biomarkers and EF in the treatment group compared to controls, with notable enhancements by day 5. However, elevated liver and kidney function markers in the treatment group suggest a need for careful monitoring. This study demonstrates the potential of integrating DSCXQ with conventional treatments to improve ACS management, although further research is necessary to establish long-term safety and efficacy.